Payment overview · 2025
General Payments
$240.53
10 reported records · 6 companies
Healthcare provider profile · identity verified
James W Mcgee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PARIS, TN · NPI 1053407890
Verified facts
What the public records show
CMS Open Payments records show James W Mcgee, MD received $240.53 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $69.49 | 28.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.00 | 25.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.50 | 20.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.16 | 10.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.76 | 7.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.62 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $195.53 | 9 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.50 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.50 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.79 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 155 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
155 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 110 |
| Omeprazole | Omeprazole | 397 | 111 |
| Lisinopril | Lisinopril | 361 | 102 |
| Simvastatin | Simvastatin | 333 | 87 |
| Furosemide | Furosemide | 332 | 104 |
| Potassium Chloride | Potassium Chloride | 329 | 89 |
| Glipizide | Glipizide | 300 | 76 |
| Losartan Potassium | Losartan Potassium | 295 | 75 |
| Gabapentin | Gabapentin | 280 | 59 |
| Metformin Hcl | Metformin Hcl | 274 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 270 | 69 |
| Alprazolam | Alprazolam | 258 | 55 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 250 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 69 |
| Famotidine | Famotidine | 242 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 75 |
| Eliquis | Apixaban | 216 | 36 |
| Valsartan | Valsartan | 203 | 52 |
| Allopurinol | Allopurinol | 201 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 168 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 39 |
| Mounjaro | Tirzepatide | 155 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 41 |
| Meloxicam | Meloxicam | 150 | 37 |
| Tramadol Hcl | Tramadol Hcl | 150 | 29 |
| Lovastatin | Lovastatin | 121 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 35 |
| Warfarin Sodium | Warfarin Sodium | 120 | 12 |
| Trazodone Hcl | Trazodone Hcl | 117 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 30 |
| Temazepam | Temazepam | 106 | 22 |
| Cephalexin | Cephalexin | 105 | 69 |
| Cefdinir | Cefdinir | 104 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 103 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 19 |
| Sertraline Hcl | Sertraline Hcl | 97 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 19 |
| Januvia | Sitagliptin Phosphate | 92 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 28 |
| Ibuprofen | Ibuprofen | 77 | 29 |
| Carvedilol | Carvedilol | 75 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | suppressed |
| Pregabalin | Pregabalin | 70 | 12 |
| Buspirone Hcl | Buspirone Hcl | 68 | 18 |
| Atenolol | Atenolol | 64 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 14 |
| Montelukast Sodium | Montelukast Sodium | 61 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 13 |
| Jardiance | Empagliflozin | 58 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 20 |
| Torsemide | Torsemide | 54 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 12 |
| Azithromycin | Azithromycin | 53 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | suppressed |
| Spironolactone | Spironolactone | 50 | 14 |
| Glimepiride | Glimepiride | 45 | 11 |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 33 |
| Meclizine Hcl | Meclizine Hcl | 43 | 20 |
| Prednisone | Prednisone | 43 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Novolog Flexpen | Insulin Aspart | 39 | 12 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 33 |
| Nystatin | Nystatin | 38 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 12 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 22 |
| Colchicine | Colchicine | 35 | 11 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 17 |
| Ozempic | Semaglutide | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Indapamide | Indapamide | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Cimetidine | Cimetidine | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 18 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 12 |
| Latanoprost | Latanoprost | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.53 · 10 records | Lilly USA, LLC | AIRSUPRA, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error